Antiprotozoal Mechanisms and Selectivity

Antiprotozoal agents are drugs used against single-celled parasites such as Plasmodium (malaria), Leishmania, the trypanosomes, Entamoeba, and Giardia. Because protozoa are eukaryotes whose biochemistry resembles the host's, achieving selective toxicity is challenging, and many antiprotozoals exploit unusual parasite metabolism, prodrug activation that occurs only inside the parasite, or targets unique to a specific parasite's life cycle.

Definition

Antiprotozoal agents are drugs that act against pathogenic protozoa by targeting parasite-specific metabolic pathways, by being selectively activated within the parasite, or by exploiting parasite stages and structures that differ from host cells, thereby achieving toxicity that spares the host.

Scope

This topic covers the mechanisms of the major antiprotozoal drug groups, the molecular basis of their selectivity for protozoa over host cells, and the principal routes by which protozoa become drug-resistant. It is an educational reference and does not provide treatment or dosing guidance.

Core questions

• What molecular targets and pathways do antiprotozoal drugs exploit?
• How do antimalarials act on the blood-stage parasite, and how is selectivity achieved?
• How do prodrug activation and parasite-specific metabolism create selective toxicity?
• What mechanisms underlie resistance in malaria, leishmaniasis, and trypanosomiasis?

Key concepts

• Haem detoxification as an antimalarial target
• Artemisinin activation by haem iron
• Antifolate inhibition of parasite folate synthesis
• Nitroheterocyclic prodrug activation inside the parasite
• Selective toxicity in a eukaryotic parasite
• Antiprotozoal drug resistance (e.g. K13, transporter changes)

Mechanisms

Antiprotozoal mechanisms vary by parasite. In malaria, blood-stage parasites digest host haemoglobin and must detoxify the liberated haem; quinoline antimalarials interfere with this detoxification, while the artemisinins are activated by haem iron into reactive intermediates that alkylate parasite proteins and lipids. Antifolate antimalarials block the parasite's own folate synthesis, a pathway the host obtains from the diet, giving selectivity. Against amoebae, Giardia, and trypanosomes, nitroheterocyclic prodrugs such as the nitroimidazoles are reduced to reactive species preferentially in the low-redox environment of anaerobic or microaerophilic parasites, damaging their DNA. Selectivity overall rests on parasite-specific pathways, parasite-restricted prodrug activation, and differential drug uptake. Resistance arises through target mutation (such as Plasmodium falciparum kelch13 changes underlying artemisinin resistance), altered drug transport, and metabolic adaptation.

Clinical relevance

Antiprotozoals underpin the global response to malaria and to neglected diseases including leishmaniasis and the trypanosomiases, so their mechanisms inform efficacy appraisal, combination strategies, and resistance surveillance. This entry describes antiprotozoal action in general educational terms and is not a basis for diagnosis, drug choice, or dosing in any individual.

Epidemiology

Malaria remains one of the largest parasitic disease burdens worldwide, with control depending heavily on artemisinin-based combination therapy; the spread of partial artemisinin resistance in Plasmodium falciparum is a major concern. Leishmaniasis and the trypanosomiases add substantial burden in tropical regions, where limited drug options and rising resistance complicate treatment.

History

Antiprotozoal chemotherapy began with quinine from cinchona bark and advanced through synthetic quinolines such as chloroquine in the mid-twentieth century. The rediscovery of artemisinin from traditional Chinese medicine, recognised with a share of the 2015 Nobel Prize, reshaped malaria treatment as chloroquine resistance spread. The subsequent identification of the kelch13 marker of artemisinin resistance marked a turn toward molecular surveillance of antiprotozoal resistance.

Debates

How should artemisinin partial resistance be contained?

The emergence of slow-clearing, kelch13-mutant Plasmodium falciparum raises debate over combination design, deployment of new partner drugs, and surveillance intensity needed to keep artemisinin-based therapy effective.

Key figures

• Tu Youyou
• Nicholas J. White
• Arjen M. Dondorp
• Michael P. Barrett

Seminal works

• white-2014
• ariey-2014

Frequently asked questions

Why is selective toxicity harder to achieve against protozoa than against bacteria?

Protozoa are eukaryotes whose cellular machinery closely resembles the human host's, so there are fewer parasite-unique targets, and drugs must rely on subtler differences in metabolism, prodrug activation, or drug uptake.

How do artemisinins act against malaria parasites?

Their peroxide bridge is activated by iron from haem in the blood-stage parasite, generating reactive intermediates that damage parasite proteins and membranes, which is why the drugs are most active where haemoglobin is being digested.